Lake Street cuts price targets on Biodesix and Starling Oncology, keeps Buy ratings
Lake Street kept Buy ratings on Biodesix and Starling Oncology but cut their price targets to $30 and $8 from $40 and $10, per TradingView data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Lake Street kept its Buy rating on Biodesix but lowered its price target to $30 from $40, a 25.0% reduction, according to TradingView. The new target implies 251.7% upside from the November 6 close of $8.53.
The same firm maintained Buy on Starling Oncology and cut its target to $8 from $10, a 20.0% decrease. Measured against the $3.62 close on the same day, the revised target implies 121.0% upside.
why it matters
Price target changes like these mainly affect the shares of the named companies and rarely move the broader market. A lower target with an unchanged Buy rating suggests the analyst expects less return from both stocks, not a reversal of the overall view. Investors usually weigh such notes alongside company results and sector developments.
tags
instruments
sources
- Lake Street maintains Biodesix at Buy, lowers price target to $30 from $40 — TradingView, 7 November 2026 at 01:27 UTC
- Lake Street maintains Starling Oncology at Buy, lowers price target to $8 from $10 — TradingView, 7 November 2026 at 01:25 UTC
- Lake Street maintains Alpha & Omega at Buy, lowers price target to $40 from $58 — TradingView, 7 November 2026 at 01:31 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗